10 September 2018: Recombinant DNA or rDNA is a type of artificial DNA developed by joining two or more DNA strands. The rDNA technology allows artificial formulation of DNA. This technology is used to alter DNAs in living organisms and is expected to have even more practical uses in future. Over the past couple of years, it has showcased major significance in bringing improvements in human life and health. The best example would be Humulin, insulin for the treatment of diabetes produced using rDNA.
Pharmaceutical and Biotech Firms Emerge as the Major Beneficiaries
Advent of recombinant DNA and various pharma products developed using this tech have revolutionized human life. The rDNA technology offers new opportunities to create medically valuable and innovative therapeutic products with immediate effect in biomedicine and medical genetics by altering plants, animals, and microorganisms. Hence, it has a wide range of end-use segments including pharmaceutical and biotechnology companies, academic and government research institutes, and others. Among these, pharma and biotech firms are the prominent users of rDNA technology as it can boost drug development capabilities of such firms.
In addition, products developed using rDNA are highly valued and have considerable improvement in productivity. Hence, biotechnology and pharmaceutical companies are expected to be the key end-users even in the future on account of growing adoption of biologics production. For example, the U.S. Food and Drug Administration (FDA) has approved Kymriah, by Novartis Corp. This is the first gene therapy available in U.S. for the treatment of leukemia. It is developed by the company in partnership with the University of Pennsylvania. Each dose of this new drug contains the patients’ own immune cells that have been modified genetically, thereby giving a second chance to the receiver.
In-Depth Research Report On Recombinant DNA Technology Market:
https://www.grandviewresearch.com/industry-analysis/recombinant-dna-technology-market
No comments:
Post a Comment